Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series

被引：6

作者：

Fu, Dian ^{[1
,2
]}

Cao, Ruiyuan ^{[3
]}

Zhao, Lei ^{[3
]}

Li, Wei ^{[3
]}

Zhong, Wu ^{[3
]}

Wen, Jiqiu ^{[1
,2
]}

机构：

[1] Nanjing Univ, Sch Med, Jinling Hosp, Natl Clin & Res Ctr Kidney Dis, Nanjing 210002, Peoples R China

[2] Wuhan Huoshenshan Hosp, Wuhan 430100, Peoples R China

[3] Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China

来源：

CRITICAL CARE | 2020年 / 24卷 / 01期

基金：

国家重点研发计划;

关键词：

Favipiravir; SARS-CoV-2; COVID-19; viral RNA persistence;

D O I：

10.1186/s13054-020-03288-5

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

[No abstract available]

引用

页数：3

共 4 条

[1] RETRACTED: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study (Retracted Article) [J].

Cai, Qingxian ;

Yang, Minghui ;

Liu, Dongjing ;

Chen, Jun ;

Shu, Dan ;

Xia, Junxia ;

Liao, Xuejiao ;

Gu, Yuanbo ;

Cai, Qiue ;

Yang, Yang ;

Shen, Chenguang ;

Li, Xiaohe ;

Peng, Ling ;

Huang, Deliang ;

Zhang, Jing ;

Zhang, Shurong ;

Wang, Fuxiang ;

Liu, Jiaye ;

Chen, Li ;

Chen, Shuyan ;

Wang, Zhaoqin ;

Zhang, Zheng ;

Cao, Ruiyuan ;

Zhong, Wu ;

Liu, Yingxia ;

Liu, Lei .

ENGINEERING, 2020, 6 (10) :1192-1198

[2]

Johns Hopkins University and Medicine, 2020, COVID- 19 map

[3] Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J].

Wang, Manli ;

Cao, Ruiyuan ;

Zhang, Leike ;

Yang, Xinglou ;

Liu, Jia ;

Xu, Mingyue ;

Shi, Zhengli ;

Hu, Zhihong ;

Zhong, Wu ;

Xiao, Gengfu .

CELL RESEARCH, 2020, 30 (03) :269-271

[4] Persistence of intestinal SARS-CoV-2 infection in patients with COVID-19 leads to re-admission after pneumonia resolved [J].

Wang, Xiaorong ;

Zhou, Yaya ;

Jiang, Nanchuan ;

Zhou, Qiong ;

Ma, Wan-Li .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 95 :433-435

← 1 →